Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: Why Gilead can’t stop talking about its ambitions in immunology

Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.

STAT+: Why Gilead can’t stop talking about its ambitions in immunology

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Thursday 24 September →